Transfusion Medicine — DCE Clinical Case

Focused history — what you must establish

• Bleeding trajectory: onset, volume and frequency of melaena, any haematemesis, syncope, exertional symptoms before collapse [1].
• Anticoagulation detail: agent, dose, adherence, last dose taken; indication (AF stroke risk, prior embolism, mechanical valve exclusion).
• Bleeding diathesis modifiers: NSAIDs, antiplatelets, alcohol, liver disease, previous GI bleeding, known ulcers or varices.
• Comorbidity that changes transfusion tolerance: ischaemic heart disease, heart failure, CKD — these change both the risk of under- and over-transfusing.
• The patient's frame: understanding of his anticoagulation, and his priorities for what comes next.

Examination priorities

Haemodynamic state and end-organ perfusion (conscious level, urine output, cool peripheries, capillary refill); signs of chronic liver disease; abdominal examination; PR for melaena confirmation; cardiac examination for failure signs that will shape transfusion speed; access sites for two large-bore cannulae [1].

Presentation template (deliver this to the examiner)

"Mr Chen is a 68-year-old man with a major upper gastrointestinal haemorrhage causing haemorrhagic shock, on therapeutic apixaban for atrial fibrillation. He is in compensated decompensating shock with a lactate of 4.2 and a 65 g/L drop from baseline. My immediate priorities are haemorrhage resuscitation with blood components, urgent endoscopy, and a decision about anticoagulant reversal. His AF thrombotic risk and the source of bleeding will drive when and how I restart anticoagulation." [1] [2]

Management — what you will actually do

1. Resuscitate: two large-bore cannulae, high-flow oxygen, bloods including group and crossmatch, coagulation profile, fibrinogen, lactate; catheterise and monitor urine output.
2. Component therapy: red cells now — thresholds do not apply to the bleeding patient. If shock persists or the bleed is massive, activate the major haemorrhage protocol and move to ratio-based packs approaching 1:1:1 on the PROPPR rationale, with fibrinogen replacement when documented low [1].
3. Reversal decision: this is life-threatening bleeding on a factor Xa inhibitor — discuss andexanet alfa where available, or prothrombin complex concentrate as the pragmatic alternative, weighing his AF stroke risk; involve haematology and gastroenterology early.
4. Definitive management: urgent upper GI endoscopy once resuscitated; treat the source (adrenaline injection, clips, thermal therapy for ulcer; banding for varices if that is the finding).
5. Aftercare and resumption: high-dose PPI infusion for ulcer bleeding; iron replacement for the chronic loss; investigate the iron-deficiency source fully if no lesion is found. Restart anticoagulation once haemostasis is secure — typically within one to two weeks with gastroenterology and cardiology input — because his AF stroke risk persists after the bleed is treated [2].

Probing questions

"Why not just reverse the apixaban immediately and watch?" — "Reversal addresses the drug, not the lesion. The sequence is resuscitate, support haemostasis — which may include reversal for life-threatening bleeding — and secure the source endoscopically. Reversal without endoscopy invites rebleeding from an untreated vessel." [1]

"How much blood will you give him?" — "Enough to restore perfusion, guided by response, not a target number. Red cells first; if this declares itself as major haemorrhage I use protocolised ratio packs and goal-directed fibrinogen and platelet replacement rather than estimating" [1].

"When is it safe to restart his apixaban?" — "When haemostasis is secure and the source is treated — in practice usually within one to two weeks, individualised with gastroenterology and cardiology, and documented as a shared decision with Mr Chen. Withholding it indefinitely trades a managed bleeding risk for an unmanaged stroke risk" [2].